Boehringer cancer drug effective in mid-stage trial

July 8 Tue Jul 8, 2014 8:18am EDT

Related Topics

July 8 (Reuters) - German drugmaker Boehringer Ingelheim said its experimental blood cancer drug met its main goal in a mid-stage trial.

Data showed the cancer was not found in 31 percent of the patients treated with the drug volasertib along with a chemotherapy agent versus 13.3 percent of patients who were administered the chemotherapy alone.

The drug was studied in 87 older patients with untreated acute myeloid leukemia, a type of blood cancer. (Reporting by Shailesh Kuber; Editing by Saumyadeb Chakrabarty)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.